Objectives: A relapse from Escherichia coli bloodstream infection was observed in a patient with acute leukaemia treated with ceftazidime for 7 days for febrile neutropenia. Whereas the original E. coli isolate was resistant to b-lactam/b-lactamase inhibitor combinations (EC1), the relapse E. coli isolate showed a similar phenotype but with resistance extended to ceftazidime (EC2). We investigated the molecular mechanisms of b-lactam resistance and sought if EC2 could have been selected in vivo from EC1.
Introduction
The penicillinase TEM-1 was described early after the clinical introduction of aminobenzylpenicillins in the 1960s and spread worldwide. 1 It is still the predominant b-lactamase in Gram-negative bacteria. 2 After the release of third-generation cephalosporins (3GCs) in the early 1980s, TEM variants carrying mutations conferring resistance to these molecules have been observed and are called extended-spectrum b-lactamases (ESBLs). 1 Similarly, the intensive use of b-lactam/b-lactamase inhibitor combinations was followed by the selection of isolates producing inhibitorresistant TEM (IRT) b-lactamases. 1 Since the mid-1990s, TEM b-lactamases combining both ESBL-and IRT-type mutations have emerged, which are commonly referred to as 'complex mutant TEMs' (CMTs). 3 To date, about 10 CMT alleles have been described (http://www.lahey.org/Studies/temtable.asp), mostly in Europe, but their prevalence is probably underestimated, given the difficulty to detect them with standard phenotypic methods. 3, 4 Many studies have shown that the selection of point mutations in TEM alleles is driven by antibiotic selection pressure in vitro, 5,6 but few reports have described this phenomenon in vivo. 7 Here, we investigated the in vivo selection of a CMT-type from an IRT-type b-lactamase that occurred in an Escherichia coli strain causing 
Case report
The patient was hospitalized for consolidation therapy of acute myeloid leukaemia in the haematology ward of Saint Louis University Hospital (Paris, France). The treatment and microbial examinations are detailed in Figure 1(a and b) . After 5 days of cancer chemotherapy associated with levofloxacin prophylaxis (500 mg/day), the patient presented neutropenia and fever and received a presumptive treatment of piperacillin/tazobactam (4 g every 6 h) for 2 days. Since the patient remained febrile, antimicrobial therapy was switched to ceftazidime (2 g every 8 h), amikacin (1.5 g/day), vancomycin (2 g/day by continuous infusion) and tinidazole (1 g/day). Blood cultures were positive for an E. coli isolate exhibiting an IRT phenotype (EC1). After 7 days of treatment, the patient showed fever again and new blood cultures yielded an E. coli isolate with a phenotype similar to that of EC1, but with resistance extended to ceftazidime (EC2) (Figure 1b) . Imipenem (1 g every 8 h) replaced ceftazidime for the following 6 days and the patient did not exhibit any signs of infection 21 days after admission.
Materials and methods
Antimicrobial susceptibility was determined using the disc diffusion method and MICs by Etest (bioMérieux, Marcy l'Étoile, France) according to French guidelines (http://www.sfm-microbiologie.org/). PCR amplification of genes encoding OXA-1-like b-lactamases, SHV and TEM (including its promoter region) was performed as previously described. DNA from EC1 and EC2 was compared by using the REP-PCR-based Diversilab w system (bioMérieux) according to the manufacturer's recommendations. The E. coli phylogenetic group was determined by multiplex PCR. 9 To investigate plasmid-mediated resistance to b-lactams, EC1 and EC2 were mated with E. coli K12DampCKan R JW4111. 10 Transconjugants were selected on Mueller-Hinton (MH) agar plates containing kanamycin (30 mg/L) and amoxicillin (100 mg/L). Plasmids were extracted from the transconjugants with the Qiagen Large-Construct Kit and were compared for EcoRI restriction profiles. The plasmids were assigned to incompatibility groups according to a PCR replicon-typing scheme. 11 Ceftazidime-resistant mutants were selected by plating 10 9 cfu onto MH agar containing from 0.25 to 8 mg/L ceftazidime (Arrow, Lyon, France). To investigate a possible hypermutable character of the strain, mutation frequencies were estimated by monitoring the strain's capacity to generate mutations conferring resistance to rifampicin in at least six independent cultures. 12 
Results and discussion
Phenotypic and genotypic comparisons of EC1 and EC2 isolates E. coli EC1 and EC2 exhibited identical antibiotic susceptibility phenotypes by the disc diffusion method except for ceftazidime resistance in EC2 (Figure 1b) . The two isolates belonged to phylogenetic group A and displayed the same REP-PCR pattern (data not shown), suggesting that EC1 and EC2 are the same strain.
EC1 and EC2 were positive for TEM-and OXA-1-type b-lactamase genes. In EC1, the TEM gene harboured the mutations M69L and N276D, corresponding to the allele TEM-35 also known as IRT-4. 13 In EC2, an additional mutation was identified: R164S known to confer ceftazidime resistance (Figure 1c) . 14 The combination of these three mutations was previously reported in the allele TEM-158, 4 also described as CMT-9 that combines resistance to b-lactamase inhibitors and 3GCs. For both strains, the nucleotide sequence and its environment showed a pattern of silent mutations identical to TEM-1b with a strong promoter, Pa/Pb. 15 Interestingly, such a pattern has been observed in the TEM-158 described by Robin et al. 4 On the basis of genomic and resistance gene findings, we presumed in vivo selection of EC2 from EC1 with occurrence of the mutation R164S.
Description of the mechanism conferring ceftazidime resistance in EC2
Resistance to b-lactams was successfully transferred from EC1 and EC2 by conjugation. Plasmids extracted from the transconjugants showed identical EcoRI restriction fragment length polymorphism (RFLP), were of the same size ( 80 kb) and were both positive for the IncP and IncFIB incompatibility groups. These results suggest that the TEM gene was carried on a conjugative plasmid where the R164S mutation has occurred. Resistance patterns to b-lactams were similar between the donors and transconjugants (Table 1) , with lower MICs observed in the transconjugants, particularly to b-lactam/b-lactam inhibitor associations and cefepime. This is due to the deletion of the ampC gene in the recipient E. coli JW4111 and the absence of OXA-1 in the transconjugants, since the OXA-1 gene was not harboured on the plasmid carrying TEM. We observed increased MICs of aztreonam, cefepime and ceftazidime in the TEM-158-producing strains (Table 1) , as described previously. 4 Nevertheless, we did not find any change in the cefotaxime MIC. This discrepancy with the previous description of TEM-158 can be due to differences in the copy number of the plasmid harbouring TEM, particularly for an enzyme with a low catalytic efficiency against cefotaxime. 4 The frequency of rifampicin-resistant mutants was similar for EC1 (4×10
210
) and the non-mutator control strain (1×10 210 ), whereas it was 6×10 27 for the mutator control strain. This showed that EC1 and EC2 are not hypermutable isolates.
In vitro selection
Ceftazidime-resistant mutants were isolated with frequencies of 10 29 for E. coli EC1 and 10 210 for E. coli JW4111(pEC1). Twelve mutants were selected from EC1 and five different single point mutations were observed in bla TEM : E166K (n¼ 6), R164H (n¼ 1), R164G (n¼ 1), R164S (n ¼1) and D179G (n¼ 3) ( Table 1) . Four mutants were selected from E. coli JW4111(pEC1) and two point mutations were observed in bla TEM : D163G (n¼ 3) and D179G (n¼ 1). No mutation was found in the promoter region.
TEM b-lactamase is composed of two domains delimiting an oxyanion pocket where the main catalytic residue (S70) is located. 16 This pocket is particularly lined by the omega loop (R161 to D179) considered to play an important role in the catalytic activity. Interestingly, the six mutations observed in the in vitro mutants were located in this omega loop. The D163G mutation was previously described in one clinical isolate and is supposed to confer resistance to ceftazidime.
14 Numerous mutants have previously been described at the R164 residue in both clinical isolates and laboratory-derived mutants (R164C, R164H, R164S, R164G, R164N and R164Y).
14 This residue has two salt-bridge interactions in the omega loop (with E171 and D179) and it was suggested that R164 mutation can lead to modification in the omega loop topology, resulting in a higher accessibility of the active site for b-lactams with larger side chains, such as 3GCs. 17 In the in vitro mutants, we observed three different mutations (R164H, R164G and R164S) at this position. The D179G mutation, observed in three mutants, is known to increase ceftazidime MICs and also to decrease resistance to penicillins. 6, 14 This mutation was only described in laboratory-derived mutants, and it has been suggested that fluctuating selective pressure of both penicillins and 3GCs could hinder the selection of such a mutation in clinical isolates. 6 We noticed that many in vitro-selected ceftazidime-resistant mutants of E. coli EC1 harboured the E166K mutation. To date, mutation at E166 has never been described either in clinical isolates or TEM-1 laboratory-derived mutants. This residue is highly conserved in class A b-lactamases and is described as a key residue in the activation of S70 during catalysis.
16 E166K may have a beneficial effect regarding the increase in ceftazidime hydrolysis when it occurs in TEM-35, whereas this mutation could be deleterious in a TEM-1 genetic background, since it has never been described.
In conclusion, we report for the first time the in vivo selection by ceftazidime of a CMT-type b-lactamase from an IRT-producing E. coli strain. Our study shows how the evolution of b-lactamase enzymes is easily driven by antibiotic pressure. Antibiotic therapy, even for 7 days, can lead to the emergence of multidrugresistant isolates. Given the results we obtained in the in vitro selection experiment and the diversity of alleles observed in clinical isolates, further investigations are required to understand the dynamics of the occurrence of mutations in CMT alleles.
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